Hence, the results of the radiopharmacological investigations of the radiolabelled DPK peptide [18F]31a in the three different murine breast cancer models suggest that this radiotracer is subject to tumour accumulation which is partially mediated by lysyl oxidases, to a similar extent as in the A375-derived melanoma model.[116] This conclusion encourages the design of radiotracers based on irreversible inhibitors derived from compound 31a in order to enhance target rentention and, consequently, image contrast of the probe. This evidence concerns the gene LOX and melanoma.